|
|
|
|
|
Click Here to return To Results
|
|
|
|
We performed yearly MRI analyses on 327 of the total 372 patients in a multicenter,randomized,double-blind,placebo-controlled trial of interferon beta-1b(IFNB).Clinical results are presented in the preceding companion paper.Baseline MRI characteristics were the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent MRIs(one every 6 weeks)for analysis of disease activity.The MRI results support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scane(median 80%reduction,p=0.0082)and appearance of new lesions.In addition,there was an equally significant reduction in MRI-detected burden of disease in the treatment as compared with placebo groups(mean difference of 213%,p=0.001).These results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients. |
|
(click to filter results - removes previous filter)
disability rating scale,neurological
interferon
interferon beta 1-b
MRI
MRI,abnormal
MRI,demyelinating disease
multiple sclerosis
multiple sclerosis,disability status scale
multiple sclerosis,relapsing
multiple sclerosis,treatment of
treatment of neurologic disorder
|
Click Here to return To Results
|
|